Overview

Board of Directors

Scientific and Clinical Advisors

Management Team

Contact Us

News

Careers

News  9/8/2011 Vaccinex to Present VX15 Preclinical MS Data at the 2011 ECTRIMS Annual Conference 8/8/2011 New BioCentury article discussing remyelinating agents in multiple sclerosis 4/1/2011 Vaccinex To Present at the American Association for Cancer Research (AACR) and the American Academy of Neurology (AAN) Annual Conferences 3/9/2011 Vaccinex To Present at the 2011 BIO-Windhover Pharmaceutical Strategic Outlook Conference 1/4/2011 Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients with Advanced Solid Tumors 11/2/2010 Vaccinex, Inc. awarded three Qualifying Therapeutic Discovery Project (QTDP) grants under the Patient Protection and Affordable Care Act of 2010 (PPACA) 10/4/2010 Vaccinex To Present at the 4th Annual Therapeutic Monoclonal Antibody Discovery Conference 6/15/2010 Vaccinex Appoints John H. Parker, PH.D. as Senior Director, Regulatory Affairs & Quality Systems 5/10/2010 Vaccinex To Present at the 6th Annual PEGS Protein Engineering Summit 1/26/2009 Vaccinex Presents Results from Preclinical Studies of Anti-CD100 Monoclonal Antibody at the Keystone Symposium on Multiple Sclerosis 1/12/2009 Vaccinex Appoints John E. Leonard, PH.D. as Senior Vice President, Development and Corporate Officer 12/8/2008 Vaccinex Presents Activmab Antibody Selection Technology at the 19th Annual IBC Antibody Engineering Conference 3/5/2008 John E. Leonard, PH.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, inc. 2/15/2008 Vaccinex Antibody Licensed to GlaxoSmithKline 11/9/2006 Vaccinex Appoints Robert B. Parker, PH.D. as Director, Regulatory Affairs & Quality Systems 10/10/2006 OPI and Vaccinex Announce License of Fully Human Anti-IL6 Antibody 5/23/2006 Vaccinex, Inc to Present at Antibody World Summit 2/10/2006 Vaccinex, Inc Announces Antibody Collaboration with Schering AG 2/15/2005 Vaccinex Names Shaun Martin as Director, Pre-Clinical Development 11/28/2004 Vaccinex and Biocon to Co-Develop Antibody Products 6/29/2004 Vaccinex and OPI Announce Antibody Collaboration 6/3/2004 Vaccinex Raises $8.4 Million in Private Financing 5/4/2004 Vaccinex Receives Second $2 Million Advanced Technology Award from the National Institute of Standards & Technology 3/25/2004 Vaccinex and University of Rochester Announce Patent Award 7/11/2003 Lonza Biologics and Vaccinex Announce Strategic Alliance 6/30/2003 Vaccinex Announces Two New Board Members 6/13/2003 Vaccinex CEO to Present at Bio 2003 Annual Convention 6/10/2002 Vaccinex, Inc. Selected to Present at Bio 2002 Investor Forum 5/14/2002 Vaccinex Opens New State-of-the-Art Research Facility and Corporate Headquarters 4/24/2002 Vaccinex Awarded NIH Grant to Study the Molecular Mechanisms Involved in Osteoporosis 1/29/2002 Vaccinex, Inc. Announces Newly Designed Web Site 9/28/2001 Vaccinex, Inc. Names R. Stanley Holland as Vice President of Finance and Chief Financial Officer 8/14/2001 Vaccinex, Inc. Names Raymond E. Watkins as Vice President of Operations and Company Officer 8/14/2001 Vaccinex Describes New Technology to Identify Cancer Targets 6/28/2001 Vaccinex Awarded Grant to Study Musculoskeletal Development 6/28/2001 Vaccinex Receives New York State Grant to Train High-tech Workers 6/21/2001 Vaccinex Awarded NIH Phase II Grant for Pre-clinical Development of a Novel Cancer Antigen 6/21/2001 Vaccinex Names Ernest S. Smith, PH.D. Research Director 5/15/2001 Governor Pataki Announces 78 New Biotech Jobs in Rochester 9/27/2000 Vaccinex, L.P. Receives $2 Million Advanced Technology Program Award